+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Branded Generics Market by Distribution Channel, Dosage Form, Therapeutic Area, Application - Global Forecast to 2030- Product Image
Branded Generics Market by Distribution Channel, Dosage Form, Therapeutic Area, Application - Global Forecast to 2030- Product Image
Sale

Branded Generics Market by Distribution Channel, Dosage Form, Therapeutic Area, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5896414
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Branded Generics Market grew from USD 494.29 billion in 2024 to USD 567.75 billion in 2025. It is expected to continue growing at a CAGR of 14.74%, reaching USD 1.12 trillion by 2030.

Setting the Stage for the 2025 Branded Generics Market

The branded generics sector has emerged as a pivotal component of global pharmaceutical portfolios, bridging the gap between patent expiry and the demand for cost-effective therapies. As price pressures and healthcare budgets tighten, branded generics offer quality assurances and recognized brand equity at reduced costs, positioning them uniquely in both developed and emerging markets. Within this shifting backdrop, stakeholders must reconcile the imperatives of affordability with the need for sustained innovation and supply chain resilience.

Against this backdrop, this executive summary establishes the framework for understanding the drivers, challenges, and strategic imperatives shaping the branded generics market in 2025. It situates key themes-such as evolving distribution channels, tariff impacts, and regional heterogeneity-within a concise analytical narrative. By anchoring our exploration in both qualitative and quantitative evidence, we lay the groundwork for deeper insights into segmentation, competitive positioning, and actionable recommendations tailored for senior executives and industry strategists.

Evolving Dynamics That Are Redefining Branded Generics

Rapid technological advancement and shifting regulatory priorities have coalesced to transform the branded generics arena. Digital disruption has accelerated patient access through online pharmacies, while mobile app-based dispensing platforms and e-commerce portals redefine traditional retail models. Simultaneously, heightened scrutiny around manufacturing standards and pharmacovigilance has compelled producers to fortify quality controls and embrace transparent traceability solutions.

Moreover, value-based healthcare initiatives are reshaping pricing frameworks and contracting practices, incentivizing outcomes over volume. This alignment of reimbursement with therapeutic efficacy has driven manufacturers to invest in differentiated dosage forms and extended-release formulations that enhance patient adherence. Meanwhile, strategic collaborations between generic and innovative pharmaceutical companies are fostering co-development ventures, blending cost efficiency with advanced formulation technologies. These transformative shifts underscore a market in motion, where agility and evidence-based differentiation determine leadership.

Assessing the Ripple Effects of 2025 US Tariff Changes

The implementation of revised United States tariff schedules in 2025 has introduced complex headwinds for branded generics producers that rely heavily on imported active pharmaceutical ingredients. Increased duties on critical intermediates have inflated input costs, prompting manufacturers to evaluate alternative sourcing strategies or absorb margin pressures. In turn, supply chains have become more localized, with contract development and manufacturing organizations expanding domestic capacity to mitigate tariff exposure.

These adjustments are not without consequence. Formulation timelines have extended as companies vet new suppliers and validate compliance with regulatory standards. At the same time, distributors and pharmacy operators are negotiating dynamic pricing arrangements to preserve patient affordability without compromising profitability. Though short-term operational disruptions have tested resilience, the industry is adapting through greater vertical integration and strategic hedging of currency and tariff risks. The net effect is a recalibrated cost structure that informs future investment and pricing decisions across the branded generics spectrum.

Decoding Market Structure Through Strategic Segmentation

A granular examination of market segmentation reveals nuanced opportunities and priorities. Distribution channels span traditional drug stores and hospital pharmacies while extending into online pharmacies, which encompass both mobile app-driven platforms and website-based dispensaries. Retail pharmacies further bifurcate into national chain networks and independent outlets, each presenting distinct service models and patient engagement strategies.

Dosage forms straddle injectable therapies-including intramuscular, intravenous, and subcutaneous applications-and liquid formulations such as suspensions and syrups that cater to pediatric and geriatric populations. Solid dosage forms combine tablets and capsules with immediate-release and extended-release technologies, while topicals cover creams, gels, and ointments designed for localized delivery and patient comfort.

Therapeutic areas span anti-infectives, subdivided into antibiotics, antifungals, and antivirals; cardiovascular agents focused on anti-dyslipidemics and anti-hypertensives; central nervous system products encompassing anti-depressants, anti-epileptics, and anti-psychotics; gastrointestinal treatments including antacids and laxatives; and pain management solutions ranging from non-opioid analgesics to controlled-substance opioids.

Applications split between human health and animal health, the latter distinguished by segments for companion animals-namely cats and dogs-and livestock care. Together, these segmentation pillars offer a multidimensional framework to guide portfolio prioritization, resource allocation, and go-to-market strategies.

Unveiling Regional Nuances Shaping Global Branded Generics

The Americas continue to exhibit robust uptake of branded generics, driven by concentrated efforts to reduce healthcare expenditures and expand access in underserved regions. Regulatory frameworks in North America increasingly emphasize product interchangeability and streamlined approvals, while Latin American markets benefit from strategic partnerships that enhance local manufacturing capabilities.

In Europe, Middle East & Africa, market maturity varies significantly. Western European nations maintain stringent quality standards and competitive tender processes, whereas emerging economies in the Middle East & Africa are in the early stages of constructing regulatory infrastructure. Investment in local production hubs and public-private partnerships is fueling capacity building, with branded generics poised to address chronic disease burdens and evolving patient expectations.

Asia-Pacific reflects some of the fastest growth trajectories, propelled by large patient populations and expanding healthcare coverage. Nations such as India and China leverage established API industries to support both domestic consumption and export demand. Meanwhile, Southeast Asian governments are enhancing reimbursement schemes and incentivizing biosimilar adoption, creating a fertile environment for branded generics that combine proven efficacy with cost advantages.

Profiling Leading Innovators in the Branded Generics Sphere

Leading players in the branded generics landscape are distinguishing themselves through integrated supply chains and ongoing investment in advanced formulation technologies. Certain multinational manufacturers have capitalized on scale to optimize unit costs while deploying quality management systems that exceed baseline regulatory requirements. Their extensive distribution networks enable rapid market entry and sustained brand visibility across diverse channels.

At the same time, agile regional companies are carving niches by tailoring offerings to local therapeutic priorities and patient demographics. These organizations often leverage partnerships with contract manufacturers and digital pharmacies to accelerate time-to-market. Collaborative ventures between established pharmaceutical firms and specialized generic producers further illustrate a trend toward co-innovation, merging core competencies to deliver differentiated products and value-added services.

Strategic Imperatives for Industry Leaders

To navigate the complexities of evolving tariffs, shifting regulatory landscapes, and intensifying competition, industry leaders must prioritize strategic supply-chain diversification and invest in dual-sourcing arrangements that mitigate geopolitical risks. Embracing digital channels through robust e-commerce platforms and telepharmacy solutions will enhance patient reach and foster brand loyalty across multiple demographics.

Portfolio optimization is equally critical; focusing on dosage forms and therapeutic areas aligned with unmet medical needs can unlock high-margin opportunities. Forming strategic alliances for co-development of novel extended-release and specialty formulations can differentiate offerings and support premium positioning. Additionally, establishing regional innovation hubs and local manufacturing joint ventures will accelerate market responsiveness and compliance.

Finally, embedding advanced analytics into demand-planning and pricing strategy allows organizations to anticipate market shifts and adapt rapidly. Continuous engagement with policymakers and healthcare payers will ensure that product pipelines remain aligned with evolving value-based reimbursement models.

Underpinning the Analysis with a Robust Methodological Framework

This analysis is grounded in a rigorous methodological framework that integrates qualitative interviews with senior executives, subject-matter experts, and key opinion leaders. Secondary research comprised a comprehensive review of regulatory filings, industry publications, and proprietary databases to validate product approvals, distribution partnerships, and technological advancements.

Data triangulation techniques were employed to reconcile potential discrepancies between primary insights and published financial disclosures. A structured segmentation approach defined distribution channels, dosage forms, therapeutic areas, and application categories to ensure consistency in cross-sectional analysis. Quality assurance protocols encompassed peer reviews, editorial audits, and iterative validation cycles to uphold analytical integrity and address potential biases.

Synthesising Insights for Strategic Decision Making

The branded generics market in 2025 is characterized by dynamic interactions among regulatory reforms, digital innovation, and shifting cost structures. Segmentation analysis reveals targeted growth pockets across distribution channels, dosage technologies, therapeutic therapies, and end-use applications. Tariff adjustments have instigated supply-chain realignments, while regional disparities underscore the importance of localized strategies.

To capture these evolving opportunities, stakeholders must align their investments with high-potential segments, fortify their supply networks against geopolitical uncertainty, and harness data-driven insights to inform product development and market entry. By synthesizing the multifaceted trends outlined in this summary, executives and decision-makers can craft resilient strategies that deliver sustainable growth and patient-centered value within the competitive branded generics domain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Distribution Channel
    • Drug Stores
    • Hospital Pharmacies
    • Online Pharmacies
      • Mobile App Pharmacies
      • Website Pharmacies
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • Dosage Form
    • Injections
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Liquids
      • Suspensions
      • Syrups
    • Tablets & Capsules
      • Extended Release
      • Immediate Release
    • Topicals
      • Creams
      • Gels
      • Ointments
  • Therapeutic Area
    • Anti-Infectives
      • Antibiotics
      • Antifungals
      • Antivirals
    • Cardiovascular
      • Anti-Dyslipidemics
      • Anti-Hypertensives
    • Central Nervous System
      • Anti-Depressants
      • Anti-Epileptics
      • Anti-Psychotics
    • Gastrointestinal
      • Antacids
      • Laxatives
    • Pain Management
      • Non-Opioid Analgesics
      • Opioids
  • Application
    • Animal Health
      • Companion Animals
        • Cats
        • Dogs
      • Livestock
    • Human Health
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Viatris Inc
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Lupin Ltd
  • Cipla Ltd
  • Aurobindo Pharma Ltd
  • Glenmark Pharmaceuticals Ltd

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Branded Generics Market, by Distribution Channel
8.1. Introduction
8.2. Drug Stores
8.3. Hospital Pharmacies
8.4. Online Pharmacies
8.4.1. Mobile App Pharmacies
8.4.2. Website Pharmacies
8.5. Retail Pharmacies
8.5.1. Chain Pharmacies
8.5.2. Independent Pharmacies
9. Branded Generics Market, by Dosage Form
9.1. Introduction
9.2. Injections
9.2.1. Intramuscular
9.2.2. Intravenous
9.2.3. Subcutaneous
9.3. Liquids
9.3.1. Suspensions
9.3.2. Syrups
9.4. Tablets & Capsules
9.4.1. Extended Release
9.4.2. Immediate Release
9.5. Topicals
9.5.1. Creams
9.5.2. Gels
9.5.3. Ointments
10. Branded Generics Market, by Therapeutic Area
10.1. Introduction
10.2. Anti-Infectives
10.2.1. Antibiotics
10.2.2. Antifungals
10.2.3. Antivirals
10.3. Cardiovascular
10.3.1. Anti-Dyslipidemics
10.3.2. Anti-Hypertensives
10.4. Central Nervous System
10.4.1. Anti-Depressants
10.4.2. Anti-Epileptics
10.4.3. Anti-Psychotics
10.5. Gastrointestinal
10.5.1. Antacids
10.5.2. Laxatives
10.6. Pain Management
10.6.1. Non-Opioid Analgesics
10.6.2. Opioids
11. Branded Generics Market, by Application
11.1. Introduction
11.2. Animal Health
11.2.1. Companion Animals
11.2.1.1. Cats
11.2.1.2. Dogs
11.2.2. Livestock
11.3. Human Health
12. Americas Branded Generics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Branded Generics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Branded Generics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Teva Pharmaceutical Industries Ltd
15.3.2. Sandoz International GmbH
15.3.3. Fresenius Kabi AG
15.3.4. Viatris Inc
15.3.5. Sun Pharmaceutical Industries Ltd
15.3.6. Dr. Reddy's Laboratories Ltd
15.3.7. Lupin Ltd
15.3.8. Cipla Ltd
15.3.9. Aurobindo Pharma Ltd
15.3.10. Glenmark Pharmaceuticals Ltd
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BRANDED GENERICS MARKET MULTI-CURRENCY
FIGURE 2. BRANDED GENERICS MARKET MULTI-LANGUAGE
FIGURE 3. BRANDED GENERICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY MOBILE APP PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY WEBSITE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DYSLIPIDEMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BRANDED GENERICS MARKET SIZE, BY HUMAN HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 104. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. CANADA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 106. CANADA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 107. CANADA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. CANADA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 109. CANADA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 110. CANADA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 111. CANADA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 112. CANADA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 113. CANADA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 114. CANADA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 115. CANADA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 116. CANADA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 117. CANADA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 118. CANADA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 120. CANADA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 207. GERMANY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. GERMANY BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 209. GERMANY BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. GERMANY BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 211. GERMANY BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 212. GERMANY BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 213. GERMANY BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 214. GERMANY BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 215. GERMANY BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 216. GERMANY BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 217. GERMANY BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 218. GERMANY BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 219. GERMANY BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 220. GERMANY BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 221. GERMANY BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. GERMANY BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 223. GERMANY BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 224. FRANCE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. FRANCE BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 226. FRANCE BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. FRANCE BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. FRANCE BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 229. FRANCE BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 231. FRANCE BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 232. FRANCE BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 233. FRANCE BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 234. FRANCE BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 235. FRANCE BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 236. FRANCE BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 237. FRANCE BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 238. FRANCE BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. FRANCE BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 240. FRANCE BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 258. ITALY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. ITALY BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 260. ITALY BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 261. ITALY BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 262. ITALY BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 263. ITALY BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 264. ITALY BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 265. ITALY BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 266. ITALY BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 267. ITALY BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 268. ITALY BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 269. ITALY BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 270. ITALY BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 271. ITALY BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 272. ITALY BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. ITALY BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 274. ITALY BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 275. SPAIN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. SPAIN BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. SPAIN BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 278. SPAIN BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 279. SPAIN BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 280. SPAIN BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 281. SPAIN BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 282. SPAIN BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 283. SPAIN BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 284. SPAIN BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 285. SPAIN BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 286. SPAIN BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 287. SPAIN BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 288. SPAIN BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 289. SPAIN BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. SPAIN BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 291. SPAIN BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 326. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 328. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 330. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2030 (USD MILLION)
TABLE 332. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 334. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 336. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2030 (USD MILLION)
TABLE 338. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2030 (USD MILLION)
TABLE 339. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 340. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 341. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2030 (USD MILLION)
TABLE 342. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 343. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)

Companies Mentioned

The companies profiled in this Branded Generics market report include:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Viatris Inc
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Lupin Ltd
  • Cipla Ltd
  • Aurobindo Pharma Ltd
  • Glenmark Pharmaceuticals Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 567.75 Billion
Forecasted Market Value ( USD ) by 2030 $ 1120 Billion
Compound Annual Growth Rate14.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 190 Pages
  • Global
From
Branded Generics - Global Strategic Business Report - Product Image

Branded Generics - Global Strategic Business Report

  • Report
  • 354 Pages
  • Global
From
Branded Generics Market Report 2025 - Product Image

Branded Generics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
2025 Global Forecast for Branded Generics (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Branded Generics (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Generic Injectables Market Report 2025-2033 - Product Image

Generic Injectables Market Report 2025-2033

  • Report
  • 125 Pages
  • Global
From

About the Branded Generics Market

Branded generics are generic drugs that are marketed under a brand name. They are typically manufactured by a generic drug company, but are sold under a brand name owned by a pharmaceutical company. Branded generics are typically sold at a higher price than generic drugs, but are still much cheaper than the original brand-name drug. They are often used to increase the market share of a generic drug company, as well as to increase the visibility of a generic drug in the marketplace. Branded generics are becoming increasingly popular in the pharmaceutical industry, as they offer a cost-effective alternative to brand-name drugs. They are also used to increase the market share of generic drug companies, as well as to increase the visibility of generic drugs in the marketplace. Some companies in the branded generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.